The documentation of 21 cases of concomitant schwannoma and hemangioma mandates the inclusion of an “Angiomatous variant of Schwannoma” under the World Health Organization classification of morphologic subtypes of schwannomas. Furthermore, the molecular cross-talk pathways and previously documented data imply that surgically inoperable schwannomas with high vascularity and/or a hemangiomatous component may benefit from targeted therapy with drugs like MEK inhibitors, mTOR inhibitors (rapamycin), NSAIDs (e.g., aspirin), and bevacizumab (VEGF monoclonal antibody). This evidence concerns the gene MAP2K7 and schwannoma.